Download PDF
Zentralbl Chir 2019; 144(03): 242-251
DOI: 10.1055/a-0883-6583
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Stereotaktische Strahlentherapie für Lebermetastasen

Stereotactic Body Radiation Therapy for Liver Metastases
David Krug
1   Klinik für Strahlentherapie, Universitätsklinikum Schleswig-Holstein, Kiel, Deutschland
3   SAPHIR Radiochirurgie Zentrum Norddeutschland, Güstrow, Deutschland
,
Oliver Blanck
1   Klinik für Strahlentherapie, Universitätsklinikum Schleswig-Holstein, Kiel, Deutschland
3   SAPHIR Radiochirurgie Zentrum Norddeutschland, Güstrow, Deutschland
,
Judit Boda-Heggemann
2   Klinik für Strahlentherapie und Radioonkologie, Universitätsmedizin Mannheim, Deutschland
,
Jürgen Dunst
1   Klinik für Strahlentherapie, Universitätsklinikum Schleswig-Holstein, Kiel, Deutschland
› Author Affiliations
Further Information

Publication History

Publication Date:
05 June 2019 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

In dieser Übersichtsarbeit wird der aktuelle Stand der stereotaktischen Strahlentherapie im Bereich des Körperstamms (SBRT) als Lokaltherapie für Patienten mit Lebermetastasen im Zustand der Oligometastasierung, Oligoprogression und Oligorekurrenz mit Fokus auf aktuelle Publikationen aus dem deutschsprachigen Raum dargelegt. Moderne SBRT-Techniken umfassen heute neben der präzisen Bildgebung auch Gating- und Tracking-Techniken, welche die Lokaltherapie von Lebermetastasen effektiver gemacht haben. Damit und mit zentralen Tumordosisoptimierungen lassen sich hohe lokale Kontrollraten von langfristig bis über 90% erreichen, die mit minimalen schweren Nebenwirkungsraten von unter 1% und 5-Jahres-Überlebensraten von mehr als 30% in selektionierten (inoperablen) Patientenkollektiven einhergehen. Durch hybride Ultraschall- oder MRT-Bestrahlungssysteme kann zukünftig die teils aktuell technisch erforderliche Fiducial-Marker-Implantation überwunden werden. Die SBRT stellt aufgrund der aktuellen Ergebnislage für Patienten mit Lebermetastasen eine wertvolle Ergänzung des therapeutischen Armamentariums als ebenbürtige Alternative zu minimalinvasiven ablativen Verfahren oder in Kombination mit anderen lokalen oder systemischen Behandlungen im interdisziplinären Kontext dar.

Abstract

In this review, the current state of stereotactic body radiation therapy (SBRT) is presented as a local therapy for patients with oligometastatic, oligoprogressive and oligorecurrent liver metastases – focusing on recent publications from German-speaking countries. In addition to precise imaging, modern SBRT techniques also use gating and tracking techniques that have made local therapy of liver metastases more effective. In combination with optimisation of central tumour dose, local control rates of up to 90% have been achieved with minimal side effects in less than 1% of patients and 5-year survival rates of more than 30% in selected (inoperable) patient populations. In future, hybrid ultrasound or MRI irradiation systems can overcome fiducial marker implantation. Due to the current outcome data, SBRT is a valuable addition to the therapeutic armamentarium for patients with liver metastases and is a true alternative to minimally invasive ablative procedures or can be used in combination with other local or systemic treatments in an interdisciplinary context.

Schlüsselwörter

Lebermetastasen - lokalablative Therapie - Oligometastasierung - stereotaktische Strahlentherapie

Key words

liver metastases - stereotactic body radiation therapy - local ablative therapy - oligometastases
 

  • Literatur

  • 1 de Ridder J, de Wilt JH, Simmer F. et al. Incidence and origin of histologically confirmed liver metastases: an explorative case-study of 23,154 patients. Oncotarget 2016; 7: 55368-55376
    CrossrefPubMedGoogle Scholar
  • 2 LeGolvan MP, Resnick M. Pathobiology of colorectal cancer hepatic metastases with an emphasis on prognostic factors. J Surg Oncol 2010; 102: 898-908
    CrossrefPubMedGoogle Scholar
  • 3 Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13: 8-10
    CrossrefPubMedGoogle Scholar
  • 4 Tomlinson JS, Jarnagin WR, DeMatteo RP. et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25: 4575-4580
    CrossrefPubMedGoogle Scholar
  • 5 Berkovic P, Gulyban A, Nguyen PV. et al. Stereotactic robotic body radiotherapy for patients with unresectable hepatic oligorecurrence. Clin Colorectal Cancer 2017; 16: 349-357
    CrossrefPubMedGoogle Scholar
  • 6 Pembroke CA, Fortin B, Kopek N. Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression. Radiother Oncol 2018; 127: 493-500
    CrossrefPubMedGoogle Scholar
  • 7 Baumann R, Koncz M, Luetzen U. et al. Oligometastases in prostate cancer: metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT. Strahlenther Onkol 2018; 194: 318-324
    CrossrefPubMedGoogle Scholar
  • 8 Stera S, Balermpas P, Chan MKH. et al. Breathing-motion-compensated robotic guided stereotactic body radiation therapy: patterns of failure analysis. Strahlenther Onkol 2018; 194: 143-155
    CrossrefPubMedGoogle Scholar
  • 9 Jiang P, Krockenberger K, Vonthein R. et al. Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial. Radiat Oncol 2017; 12: 138
    CrossrefPubMedGoogle Scholar
  • 10 Gkika E, Adebahr S, Kirste S. et al. Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer: a toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT. Strahlenther Onkol 2017; 193: 433-443
    CrossrefPubMedGoogle Scholar
  • 11 Sterzing F, Brunner TB, Ernst I. et al. Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 2014; 190: 872-881
    CrossrefPubMedGoogle Scholar
  • 12 Gkika E, Bettinger D, Krafft L. et al. The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. Strahlenther Onkol 2018; 194: 403-413
    CrossrefPubMedGoogle Scholar
  • 13 Brunner TB, Blanck O, Lewitzki V. et al. Stereotactic body radiotherapy dose and its impact on local control and overall survival for patients with locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiother Oncol 2019; 132: 42-47
    PubMedGoogle Scholar
  • 14 Chiang CL, Chan MKH, Yeung CSY. et al. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B–C hepatocellular carcinoma. Strahlenther Onkol 2019; 195: 254-264
    CrossrefPubMedGoogle Scholar
  • 15 Gkika E, Strouthos I, Kirste S. et al. Repeated SBRT for in- and out-of-field recurrences in the liver. Strahlenther Onkol 2019; 195: 246-253
    CrossrefPubMedGoogle Scholar
  • 16 Boda-Heggemann J, Dinter D, Weiss C. et al. Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases – clinical results. Radiat Oncol 2012; 7: 92
    CrossrefPubMedGoogle Scholar
  • 17 Habermehl D, Herfarth KK, Bermejo JL. et al. Single-dose radiosurgical treatment for hepatic metastases–therapeutic outcome of 138 treated lesions from a single institution. Radiat Oncol 2013; 8: 175
    CrossrefPubMedGoogle Scholar
  • 18 Andratschke NH, Nieder C, Heppt F. et al. Stereotactic radiation therapy for liver metastases: factors affecting local control and survival. Radiat Oncol 2015; 10: 69
    CrossrefPubMedGoogle Scholar
  • 19 Andratschke N, Parys A, Stadtfeld S. et al. Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases. Radiat Oncol 2016; 11: 74
    CrossrefPubMedGoogle Scholar
  • 20 Stintzing S, Einem JV, Fueweger C. et al. Long-term survival in patients treated with a robotic radiosurgical device for liver metastases. Cancer Res Treat 2019; 51: 187-193
    CrossrefPubMedGoogle Scholar
  • 21 Scorsetti M, Comito T, Clerici E. et al. Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up. Radiat Oncol 2018; 13: 234
    CrossrefPubMedGoogle Scholar
  • 22 Mahadevan A, Blanck O, Lanciano R. et al. Stereotactic body radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® Patient Registry. Radiat Oncol 2018; 13: 26
    CrossrefPubMedGoogle Scholar
  • 23 Andratschke N, Alheid H, Allgäuer M. et al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer 2018; 18: 283
    CrossrefPubMedGoogle Scholar
  • 24 Palma DA, Olson RA, Harrow S. et al. Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial. Int J Radiat Oncol Biol Phys 2018; 102 (Suppl.) S3-S4
    CrossrefPubMedGoogle Scholar
  • 25 Robin TP, Raben D, Schefter TE. A contemporary update on the role of stereotactic body radiation therapy (SBRT) for liver metastases in the evolving landscape of oligometastatic disease management. Semin Radiat Oncol 2018; 28: 288-294
    CrossrefPubMedGoogle Scholar
  • 26 Klement R, Guckenberger M, Alheid H. et al. Stereotactic body radiotherapy for oligo-metastatic liver disease – influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol 2017; 123: 227-233
    CrossrefPubMedGoogle Scholar
  • 27 Méndez Romero A, Verheij J, Dwarkasing RS. et al. Comparison of macroscopic pathology measurements with magnetic resonance imaging and assessment of microscopic pathology extension for colorectal liver metastases. Int J Radiat Oncol Biol Phys 2012; 82: 159-166
    CrossrefPubMedGoogle Scholar
  • 28 Chan MK, Grehn M, Cremers F. et al. Dosimetric implications of residual tracking errors during robotic SBRT of liver metastases. Int J Radiat Oncol Biol Phys 2017; 97: 839-848
    CrossrefPubMedGoogle Scholar
  • 29 Henke L, Kashani R, Robinson C. et al. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol 2018; 126: 519-526
    CrossrefPubMedGoogle Scholar
  • 30 Sihono DS, Vogel L, Weiß C. et al. A 4D ultrasound real-time tracking system for external beam radiotherapy of upper abdominal lesions under breath-hold. Strahlenther Onkol 2017; 193: 213-220
    CrossrefPubMedGoogle Scholar
  • 31 Ipsen S, Bruder R, OʼBrien R. et al. Online 4D ultrasound guidance for real-time motion compensation by MLC tracking. Med Phys 2016; 43: 5695
    CrossrefPubMedGoogle Scholar
  • 32 Chan MK, Lee V, Chiang CL. et al. Lipiodol versus diaphragm in 4D-CBCT-guided stereotactic radiotherapy of hepatocellular carcinomas. Strahlenther Onkol 2016; 192: 92-101
    CrossrefPubMedGoogle Scholar
  • 33 Jarraya H, Chalayer C, Tresch E. et al. Novel technique for hepatic fiducial marker placement for stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2014; 90: 119-125
    CrossrefPubMedGoogle Scholar
  • 34 Moustakis C, Blanck O, Andratschke A. et al. Reference plan comparison study for liver SBRT – results of the DEGRO/DGMP working groups for stereotactic radiotherapy. Strahlenther Onkol 2018; 194: 18-19
    PubMedGoogle Scholar
  • 35 Boda-Heggemann J, Attenberger U, Budjan J. et al. MRI morphologic alterations after liver SBRT: Direct dose correlation with intermodal matching. Strahlenther Onkol 2016; 192: 641-648
    CrossrefPubMedGoogle Scholar
  • 36 Boda-Heggemann J, Jahnke A, Chan M. et al. Direct dose correlation of MRI morphologic alterations of healthy liver tissue after robotic liver SBRT. Strahlenther Onkol 2018; 194: 414-424
    CrossrefPubMedGoogle Scholar
  • 37 Boda-Heggemann J, Jahnke A, Chan M. et al. In-vivo treatment accuracy analysis of active motion-compensated liver SBRT through registration of plan dose to post-therapeutic MRI-morphologic alterations. Radiother Oncol 2019; DOI: 10.1016/j.radonc.2019.01.023. [in press]
    CrossrefPubMedGoogle Scholar
  • 38 Jung J, Kim H, Yoon SM. et al. Targeting accuracy of image-guided stereotactic body radiation therapy for hepatocellular carcinoma in real-life clinical practice: in vivo assessment using hepatic parenchymal changes on Gd-EOB-DTPA-enhanced magnetic resonance images. Int J Radiat Oncol Biol Phys 2018; 102: 867-874
    CrossrefPubMedGoogle Scholar
  • 39 Hong TS, Wo JY, Borger DR. et al. Phase II study of proton-based stereotactic body radiation therapy for liver metastases: importance of tumor genotype. J Natl Cancer Inst 2017; 109 DOI: 10.1093/jnci/djx031.
    CrossrefPubMedGoogle Scholar
  • 40 Ohri N, Tomé WA, Méndez Romero A. et al. Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys 2018; DOI: 10.1016/j.ijrobp.2017.12.288.
    CrossrefPubMedGoogle Scholar
  • 41 Klement RJ. Radiobiological parameters of liver and lung metastases derived from tumor control data of 3719 metastases. Radiother Oncol 2017; 123: 218-226
    CrossrefPubMedGoogle Scholar
  • 42 Klement R, Abbasi-Senger N, Adebahr S. et al. The impact of local control on overall survival after stereotatic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC Cancer 2019; 19: 173 doi:10.1186/s12885-019-5362-5
    CrossrefPubMedGoogle Scholar
  • 43 Helou J, Thibault I, Chu W. et al. Quality of life changes after stereotactic ablative radiotherapy for liver metastases: A prospective cohort analysis. Radiother Oncol 2018; 129: 435-440
    CrossrefPubMedGoogle Scholar
  • 44 Zaydfudim VM, McMurry TL, Harrigan AM. et al. Improving treatment and survival: a population-based study of current outcomes after a hepatic resection in patients with metastatic colorectal cancer. HPB (Oxford) 2015; 17: 1019-1024
    CrossrefPubMedGoogle Scholar
  • 45 Kassahun WT. Controversies in defining prognostic relevant selection criteria that determine long-term effectiveness of liver resection for noncolorectal nonneuroendocrine liver metastasis. Int J Surg 2015; 24: 85-90
    CrossrefPubMedGoogle Scholar
  • 46 Beermann M, Lindeberg J, Engstrand J. et al. 1000 consecutive ablation sessions in the era of computer assisted image guidance – lessons learned. Eur J Radiol Open 2018; 6: 1-8
    PubMedGoogle Scholar
  • 47 Seidensticker R, Damm R, Enge J. et al. Local ablation or radioembolization of colorectal cancer metastases: comorbidities or older age do not affect overall survival. BMC Cancer 2018; 18: 882
    CrossrefPubMedGoogle Scholar
  • 48 White J, Carolan-Rees G, Dale M. et al. Analysis of a national programme for selective internal radiation therapy for colorectal cancer liver metastases. Clin Oncol (R Coll Radiol) 2019; 31: 58-66
    CrossrefPubMedGoogle Scholar
  • 49 Wasan HS, Gibbs P, Sharma NK. et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol 2017; 18: 1159-1171
    CrossrefPubMedGoogle Scholar
  • 50 Franzese C, Comito T, Clerici E. et al. Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation. J Cancer Res Clin Oncol 2018; 144: 1777-1783
    CrossrefPubMedGoogle Scholar
  • 51 Jackson WC, Tao Y, Mendiratta-Lala M. et al. Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases. Int J Radiat Oncol Biol Phys 2018; 100: 950-958
    CrossrefPubMedGoogle Scholar
  • 52 Ruers T, Van Coevorden F, Punt CJ. et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst 2017; 109 DOI: 10.1093/jnci/djx015. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial
    CrossrefPubMedGoogle Scholar
  • 53 Goody RB, Brade AM, Wang L. et al. Phase I trial of radiation therapy and sorafenib in unresectable liver metastases. Radiother Oncol 2017; 123: 234-239
    CrossrefPubMedGoogle Scholar